Hodgkin's Disease Clinical Trial
Official title:
A Phase I Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
This trial is a prospective, open-label, single-arm trial of the safety of a single FT1050-treated CB unit for hematopoietic reconstitution after a reduced-intensity conditioning regimen for hematologic malignancies. A maximum of 40 eligible adult subjects will be enrolled and treated in the trial at approximately 2-4 centers within the U.S.
The trial will be conducted in three sequential cohorts of 6-12 evaluable subjects each.
Cohort 1 will enroll eligible subjects for whom a single CB unit has been identified that
meets the minimum HLA-matching criteria and has a minimum pre-cryopreservation total
nucleated cell (TNC) dose of at least 2.5 x 10^7 cells/kg. Cohort 2 is identical to Cohort
1, except that the TNC dose of the CB unit must be between 2.0 - <2.5 x 10^7 cells/kg.
Finally, Cohort 3 is identical to Cohort 2, except that the TNC dose of the CB unit must be
between 1.5 - <2.0 x 10^7 cells/kg. If no safety rules are triggered, the study will proceed
to the next dosing cohort. Within a dosing cohort, no more than three subjects may be before
Day 42 at any one time, unless they have already engrafted neutrophils. The final dosing
cohort is defined as the last cohort where 12 evaluable subjects are treated and no stopping
rules are triggered. The corresponding TNC dose level will be considered the minimally
acceptable TNC dose level.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01665768 -
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
|
Phase 2 | |
Completed |
NCT01188798 -
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
|
Phase 3 | |
Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
Completed |
NCT00150462 -
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
|
Phase 1 | |
Completed |
NCT00606437 -
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
|
Phase 1 | |
Completed |
NCT02856646 -
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
|
||
Completed |
NCT01458288 -
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
|
Phase 2 | |
Completed |
NCT00990587 -
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
|
Phase 1 | |
Terminated |
NCT00594308 -
In-Vivo Activated T-Cell Depletion to Prevent GVHD
|
N/A | |
Completed |
NCT00469729 -
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
|
Phase 2/Phase 3 | |
Completed |
NCT00552825 -
Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children
|
N/A | |
Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A | |
Completed |
NCT00165438 -
Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy
|
N/A | |
Recruiting |
NCT02007811 -
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
|
Phase 1/Phase 2 | |
Completed |
NCT01221857 -
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00665314 -
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).
|
Phase 2 | |
Completed |
NCT00569842 -
Investigation of the Cylex® ImmuKnow® Assay
|
N/A | |
Completed |
NCT00256191 -
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00284804 -
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
|
Phase 2 | |
Completed |
NCT00396201 -
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease
|
Phase 2 |